Candel Therapeutics, Inc. CADL
We take great care to ensure that the data presented and summarized in this overview for Candel Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CADL
View all-
Acorn Capital Advisors, LLC New York, NY2.58MShares$14.3 Million8.54% of portfolio
-
Northpond Ventures, LLC1.94MShares$10.8 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.79MShares$9.94 Million0.0% of portfolio
-
Portolan Capital Management, LLC Boston, MA1.62MShares$9.02 Million0.59% of portfolio
-
Geode Capital Management, LLC Boston, MA904KShares$5.03 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$4.58 Million0.0% of portfolio
-
Halter Ferguson Financial Inc. Carmel, IN698KShares$3.88 Million0.81% of portfolio
-
State Street Corp Boston, MA652KShares$3.63 Million0.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA406KShares$2.26 Million0.66% of portfolio
-
Two Sigma Investments, LP New York, NY369KShares$2.05 Million0.0% of portfolio
Latest Institutional Activity in CADL
Top Purchases
Top Sells
About CADL
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Insider Transactions at CADL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 28
2025
|
William Garrett Nichols Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
937
-1.75%
|
$5,622
$6.98 P/Share
|
|
Jul 28
2025
|
William Garrett Nichols Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
937
+1.72%
|
$937
$1.29 P/Share
|
|
Jun 30
2025
|
William Garrett Nichols Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
781
-1.47%
|
$3,905
$5.04 P/Share
|
|
Jun 30
2025
|
William Garrett Nichols Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
781
+1.44%
|
$781
$1.29 P/Share
|
|
Jun 25
2025
|
Joseph C Papa |
BUY
Grant, award, or other acquisition
|
Indirect |
64,239
+50.0%
|
$256,956
$4.67 P/Share
|
|
Jun 25
2025
|
Francesca Barone Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,282
+4.07%
|
$17,128
$4.67 P/Share
|
|
Jun 25
2025
|
Gary J. Nabel |
BUY
Grant, award, or other acquisition
|
Direct |
5,353
+50.0%
|
$21,412
$4.67 P/Share
|
|
Jun 25
2025
|
Nicoletta Loggia |
BUY
Grant, award, or other acquisition
|
Direct |
2,141
+50.0%
|
$8,564
$4.67 P/Share
|
|
Jun 25
2025
|
Charles Schoch Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,353
+10.98%
|
$21,412
$4.67 P/Share
|
|
Jun 25
2025
|
Christopher Martell |
BUY
Grant, award, or other acquisition
|
Indirect |
111,349
+50.0%
|
$445,396
$4.67 P/Share
|
|
Jun 25
2025
|
Paul B Manning |
BUY
Grant, award, or other acquisition
|
Indirect |
1,070,663
+32.61%
|
$4,282,652
$4.67 P/Share
|
|
Jun 25
2025
|
Paul Peter Tak Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,826
+13.75%
|
$171,304
$4.67 P/Share
|
|
Jun 25
2025
|
Seshu Tyagarajan Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,353
+5.56%
|
$21,412
$4.67 P/Share
|
|
Mar 19
2025
|
Paul Peter Tak Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
400
-0.18%
|
$3,600
$9.0 P/Share
|
|
Mar 18
2025
|
Paul Peter Tak Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,772
-10.23%
|
$206,176
$8.77 P/Share
|
|
Mar 18
2025
|
Francesca Barone Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
32,146
-24.98%
|
$257,168
$8.76 P/Share
|
|
Mar 18
2025
|
Francesca Barone Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+12.27%
|
$18,000
$1.55 P/Share
|
|
Mar 18
2025
|
William Garrett Nichols Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
45,316
-46.33%
|
$362,528
$8.76 P/Share
|
|
Mar 18
2025
|
William Garrett Nichols Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,489
+8.81%
|
$36,978
$2.52 P/Share
|
|
Mar 17
2025
|
Seshu Tyagarajan Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
31,278
-26.78%
|
$250,224
$8.82 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.31M shares |
|---|---|
| Open market or private purchase | 1.25M shares |
| Exercise of conversion of derivative security | 51.1K shares |
| Sale (or disposition) back to the issuer | 50K shares |
| Open market or private sale | 387K shares |
|---|---|
| Sale (or disposition) back to the issuer | 1.6M shares |